Not Yet Recruiting
A Study to Assess the Pharmacokinetics, Safety and Tolerability of Single-dose Adagrasib (BMS-986503) in Healthy Participants of Japanese Descent - CA239-0028
Actualizada: 20 julio, 2026 | ClinicalTrials.gov
Fase
Géneros
Rango de edad
Ubicación (es)
Not Yet Recruiting
Inclusion Criteria: - Participants must be of Japanese descent (both biological parents of the participant are ethnically Japanese). - Participants must be healthy adult without clinically significant deviation from normal in medical history, PE, 12-lead ECG, vital sign measurements, and clinical laboratory assessments as determined by the investigator. - Participants must have Body mass index of 18.0 kg/m2 to 32.0 kg/m2. - Participants must have Total body weight ≥ 50 kg. Exclusion Criteria: - Participants must not have significant history or clinical manifestation of any metabolic, allergic, dermatological, renal, hematological, pulmonary, cardiovascular, gastrointestinal, neurological, respiratory, endocrine, or psychiatric disorder, as determined by the investigator. - Other protocol defined Inclusion/Exclusion criteria apply.
Recomendamos encarecidamente que se comunique con BMS para informar los efectos secundarios (eventos adversos)
Los efectos secundarios (eventos adversos) y otros eventos reportables se definen aquí
Informe de efectos secundarios (eventos adversos) o quejas sobre la calidad del producto: información médica
